Key result
Intramyocardial injection of mesenchymal stem cell-seeded hydrogel significantly improved left ventricular ejection fraction to 68.5% compared to 47.4% with PBS at 56 days post-myocardial infarction.
Why the study?
Does intramyocardial injection of MSC-seeded Si-HPMC hydrogel improve cardiac function and attenuate LV remodeling in a rat model of myocardial infarction?
Does intramyocardial injection of MSC-seeded Si-HPMC hydrogel improve cardiac function and attenuate LV remodeling in a rat model of myocardial infarction?
Absolute Event Rate: 68.5% vs 47.4%
p-value: p=<0.001
Intramyocardial delivery of MSCs in a Si-HPMC hydrogel scaffold improves cell engraftment, preserves cardiac function, and attenuates adverse remodeling after myocardial infarction in a rat model.
May support scaffolded MSC delivery in rodent MI models; leaves open translation to larger species or humans.
BACKGROUND: To improve the efficacy of bone marrow-derived mesenchymal stem cell (MSC) therapy targeted to infarcted myocardium, we investigated whether a self-setting silanized hydroxypropyl methylcellulose (Si-HPMC) hydrogel seeded with MSC (MSC+hydrogel) could preserve cardiac function and attenuate left ventricular (LV) remodeling during an 8-week follow-up study in a rat model of myocardial infarction (MI). METHODOLOGY/PRINCIPAL FINDING: Si-HPMC hydrogel alone, MSC alone or MSC+hydrogel were injected into the myocardium immediately after coronary artery ligation in female Lewis rats. Animals in the MSC+hydrogel group showed an increase in cardiac function up to 28 days after MI and a mid-term prevention of cardiac function alteration at day 56. Histological analyses indicated that the injection of MSC+hydrogel induced a decrease in MI size and an increase in scar thickness and ultimately limited the transmural extent of MI. These findings show that intramyocardial injection of MSC+hydrogel induced short-term recovery of ventricular function and mid-term attenuation of remodeling after MI. CONCLUSION/SIGNIFICANCE: These beneficial effects may be related to the specific scaffolding properties of the Si-HPMC hydrogel that may provide the ability to support MSC injection and engraftment within myocardium.
No takes yet. Share an insight, caveat, or question.
Mathieu et al. (2012) studied Myocardial Infarction (n=62). Mesenchymal stem cell-seeded Si-HPMC hydrogel vs. PBS (control), hydrogel alone, or MSC alone was evaluated on Left ventricular ejection fraction (LVEF) at 56 days (p=<0.001). Intramyocardial injection of mesenchymal stem cell-seeded hydrogel significantly improved left ventricular ejection fraction to 68.5% compared to 47.4% with PBS at 56 days post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: